

1. Auswahl

2. Auswahl

- Ovarialkarzinom

OP
1st-line Behandlung
Platin-geeignetes Rezidiv
Nicht-platin-geeignetes Rezidiv
Nicht-epithelial
Nicht-interventionell

- Endometriumkarzinom

OP
Adjuvante Therapie
Rezidiv-Therapie
Nicht-interventionell

- Zervixkarzinom

OP
Adjuvante Therapie
Rezidiv-Therapie

- Anderes

Pazodoble
REGSA

Ovarialkarzinom

OP

Keine

1st-line

AGO-OVAR 28 / ENGOT-ov57

Niraparib vs Niraparib in combination with Bevacizumab in patients with carboplatinum-taxane based chemotherapy in advanced ovarian cancer (A multicentre randomised phase III trial)

AGO-OVAR 27

Window-of-opportunity proof-of-concept, non-randomized, open-label, phase II trial of Olaparib given alone (cohort A) or in combination with Durvalumab (cohort B) prior to primary debulking surgery in histologically proven high-grade epithelial ovarian cancer (EOC)

WoO: Window of Opportunity trial of Olaparib and Durvalumab
in histologically proven EOC

MATAO (in Vorbereitung)

MAintenance Therapy with Aromatase inhibitor in epithelial Ovarian cancer: a randomized double-blinded placebo-controlled multi-center phase III Trial (ENGOT-ov54/Swiss-GO-2/MATAO) including LOGOS (Low Grade Ovarian cancer Sub-study)

Ovarialkarzinom

Platin-geeignetes Rezidiv

MIROVA AGO-OVAR 2.34

A randomized phase II trial of Mirvetuximab soravtansine (IMGN853), in folate receptor alpha (FR α) high recurrent ovarian cancer eligible for platinum-based chemotherapy. MIRvetuximab soravtansine in OVARian Cancer

NEWTON study

A MULTICENTER, OPEN-LABEL PHASE II TRIAL OF A NEW CUSTOMIZED DOSING (RATIONAL ADJUSTMENT OF DOSE TO REDUCE ADVERSE REACTIONS “RADAR” DOSING) OF NIRAPARIB AS MAINTENANCE THERAPY IN PLATINUM SENSITIVE OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL RECURRENT CANCER PATIENTS

(NEW dosing mainTenance therapy Ovarian caNcer)

Low-grade

PERCEPTION

Phase II investigational study of pembrolizumab combination with chemotherapy in platinum-sensitive recurrent low-grade serous ovarian cancer

Ovarialkarzinom

Nicht-platin-geeignetes Rezidiv

EPIK-O (Green Light fehlt)

Eine multizentrische, randomisierte (1:1), open-label, aktiv kontrollierte Phase III Studie zur Untersuchung der Wirksamkeit und Sicherheit von Alpelisib (BYL719) in Kombination mit Olaparib im Vergleich zu zytotoxischen Mono-Chemotherapien bei Patientinnen mit einem platinresistenten oder –refraktären hochgradig serösen Ovarialkarzinom, bei dem keine BRCA Mutation in der Keimbahn nachgewiesen wurde

ENGOT-OV56/NSGO-CTU-DOVACC (in Vorbereitung)

A Randomized Clinical Trial Investigating Olaparib, Durvalumab (MEDI4736) and UV1 as Maintenance Therapy in BRCAwt Patients with Recurrent Ovarian Cancer

AGO-2.41/TEDOVA (in Vorbereitung)

Randomized Phase II study comparing neo-epitope based vaccine OSE2101 (TEDOPI®) with or without anti-PD1 (Pembrolizumab) versus best supportive care as maintenance treatment in platinum-sensitive recurrent ovarian cancer patient with controlled disease after Platinum-based chemotherapy.

OncXerna Therapeutics, Inc. (in Vorbereitung, actually on Hold)

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY OF NAVICIXIZUMAB PLUS PACLITAXEL AND NAVICIXIZUMAB MONOTHERAPY IN COMPARISON TO PACLITAXEL MONOTHERAPY IN PATIENTS WITH PLATINUM-RESISTANT EPITHELIAL OVARIAN, PRIMARY PERITONEAL, OR FALLOPIAN TUBE CANCER”

ARTISTRY-7 / ENGOT-ov68 (in Vorbereitung)

A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator’s Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARTISTRY-7)

Ovarialkarzinom

Nicht-epithelial

MAKEI V

Phase III Studie Carbo vs Cisplatin Kombi mit Etoposid und Ifosfamid bei chemotherapie-naivem extrakraniell malignen Keimzelltumor

Nicht-interventionell

NOGGO S15 FraStrROC

Development and prospective validation of a Frailty Score for chemotherapy associated side effects in Relapsed Ovarian Cancer Study participants recommended for mono-chemotherapy with either Paclitaxel, PLD, Topotecan or Treosulfan and with optional use of Bevacizumab according to decision of the treating physician and following approval and who should start therapy within 2 weeks of registration in this trial. All therapies are as standard of care. At least 1 prior treatment regimen for ovarian cancer (i.e. up from second line treatment is allowed)

HELP-ER

Prospective Study of HE4 serum Level in Patients with First Platinum Sensitive Relapsed Ovarian Cancer

Endometriumkarzinom

OP

ECLAT

Pelvic and Para-aortic Lymphadenectomy in Patients with Stage I or II Endometrial Cancer with High Risk of Recurrence

Adjuvante Therapie

Keine

Rezidiv-Therapie

Keine

Nicht-interventionell

AGO-TR 2

Prävalenz von somatischen und Keimbahnmutationen bei Patientinnen mit primär- oder rezidiviertem Endometriumkarzinom

Zervixkarzinom

OP

SENTICOL III (Green Light fehlt)

International validation study of sentinel node biopsy in early cervical cancer.

Adjuvante Therapie

Keine

Rezidiv-Therapie

AGO-ZX-4 / ENGOT-Cx12 SGNTV-003

A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator's Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer

Anderes

Uterines Leiomyosarkom/uterines Karzinosarkom

Rezidivtherapie

Pazodoble II

Pazopanib vs. Pazopanib plus Gemcitabine in patients with relapsed or metastatic uterine leiomyosarcomas or uterine carcinosarcomas: a multi-center, randomized phase-II clinical trial of the NOGGO and AGO – PazoDoble

Nicht-interventionell

REGSA

Deutsche prospektive Registerstudie zur Erfassung der Behandlungspraxis von gynäkologischen Sarkomen in der klinischen Routine (REGSA)